secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001171843-23-002089
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharma reduces CEO salary from $300K to $34,840; grants 800K options
---------------------------------------------------------------------------

- CEO base salary cut to $34,840/year effective March 31, 2023, from $300,000.
- Option to purchase 800,000 shares granted, vesting monthly over 36 months.
- Compensation Committee approved the changes on March 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323002089/0001171843-23-002089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323002089/f8k_040323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer